Cases & Deals

Share

UCB completes €3 billion EMTN Programme

October 2019

Client(s) UCB S.A.

Jones Day advised UCB S.A. in connection with the set-up of their €3 billion EMTN Programme for issuance of notes. UCB S.A. is a global biopharmaceutical company, headquartered in Brussels (Belgium) and listed on Euronext Brussels (part of the Bel 20 index). The UCB Group develops and markets human pharmaceutical products for the treatment of severe central nervous system (CNS) and immunology disorders.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.